scholarly journals Fibrinolytic Potential and Antiphospholipid Antibodies in Systemic Lupus Erythematosus and Other Connective Tissue Disorders

1992 ◽  
Vol 68 (05) ◽  
pp. 516-520 ◽  
Author(s):  
M Jurado ◽  
J A Páramo ◽  
M Gutierrez-Pimentel ◽  
E Rocha
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Connective Tissue ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Venous Occlusion ◽  
Tissue Type ◽  
Control Group ◽  
Connective Tissue Disorders ◽  
Systemic Lupus ◽  
Pai 1

SummaryWe studied the fibrinolytic response before and after venous occlusion (VO) in 30 patients with systemic lupus erythematosus (SLE), 25 with rheumatoid arthritis (RA) and 25 with different connective tissue disorders. Results were compared in patients with and without antiphospholipid antibodies (APA) and a history of either thrombosis or abortions. Before occlusion plasma levels of tissue-type plasminogen activator (t-PA) antigen and its inhibitor (PAI-1) were significantly higher in the patient group (p <0.001). After occlusion, a low fibrinolytic activity on fibrin plates (p <0.005) was observed in the same group. t-PA capacity and t-PA release were similar in relation to controls. The plasma PAI-1 activity was significantly elevated in each group of patients (p <0.005) as compared to the control group. No significant differences with respect to t-PA and PAI-1 were observed in patients as to the presence or absence of thrombosis. There was also no correlation between the fibrinolytic changes and the presence of APA. It is concluded that an impairment of the fibrinolytic system, mainly related to increased PAI-1 levels, is present in most patients with connective tissue disorders, although these changes did not correlate with the presence of APA or the incidence of thrombosis.

scholarly journals Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies

2020 ◽  
Vol 9 (10) ◽  
pp. 3297
Author(s):  
Elena Monzón Manzano ◽  
Ihosvany Fernández-Bello ◽  
Raúl Justo Sanz ◽  
Ángel Robles Marhuenda ◽  
Francisco Javier López-Longo ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Thrombin Generation ◽  
Thrombotic Event ◽  
Systemic Lupus ◽  
Activation Markers ◽  
Global Tests ◽  
Platelet Aggregates ◽  
Pai 1

We aimed to identify the key players in the prothrombotic profile of patients with systemic lupus erythematosus (SLE) not mediated by antiphospholipid antibodies, as well as the potential utility of global coagulation tests to characterize hemostasis in these patients. Patients with SLE without antiphospholipid antibodies and without signs of thrombosis were included. The kinetics of clot formation were determined by ROTEM®. Platelet activation markers were determined by flow cytometry. Thrombin generation associated with Neutrophil Extracellular Traps (NETs) and microparticles (MPs) was measured by calibrated automated thrombogram (CAT). The plasma levels of PAI-1 were also determined. ROTEM® showed a procoagulant profile in SLE patients. SLE patients had activated platelets and more leukocyte/platelet aggregates at basal conditions. The plasma PAI-1 and platelet aggregates correlated with several ROTEM® parameters. The thrombin generation associated withthe tissue factor (TF) content of MPs and with NETs was increased. Our results suggest the utility of global tests for studying hemostasis in SLE patients because they detect their procoagulant profile, despite having had neither antiphospholipid antibodies nor any previous thrombotic event. A global appraisal of hemostasis should, if possible, be incorporated into clinical practice to detect the risk of a thrombotic event in patients with SLE and to consequently act to prevent its occurrence.

Bone, joint, and connective tissue disorders

2018 ◽  
Author(s):  
Colin Berry
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Ankylosing Spondylitis ◽  
Connective Tissue ◽  
Musculoskeletal Disorders ◽  
Lupus Erythematosus ◽  
Anaesthetic Management ◽  
Connective Tissue Disorders ◽  
Systemic Lupus

This chapter describes the anaesthetic management of the patient with those musculoskeletal disorders which are relevant to anaesthetic practice. Topics covered include rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic sclerosis, scoliosis, and achondroplasia. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described.

scholarly journals Serum markers thrombophilia in pregnant women with Systemic Lupus Erythematosus

2017 ◽  
Vol 17 (4) ◽  
pp. 833-842
Author(s):  
Vanessa Marcon de Oliveira ◽  
Ernesto Antonio Figueiró-Filho ◽  
Cristiane Munaretto Ferreira ◽  
Erica Freire de Vasconcelos Pereira
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pregnant Women ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Serum Markers ◽  
Control Group ◽  
Systemic Lupus ◽  
Exact Test ◽  
Hereditary Thrombophilia ◽  
Acquired Thrombophilia

Abstract Objectives: to determine the frequency of serum markers for hereditary and acquired thrombophilia and their association with pregnancy in women with Systemic Lupus Erythematosus (SLE). Methods: a case-control study was conducted among 25 pregnant women with SLE (study group) and 32 pregnant women without known disease and with at least one previous pregnancy (control group). The presence of antiphospholipid antibodies and hereditary thrombophilia were examined in both groups. We used the y2 Test with Yates correction or Fisher's Exact Test to verify the associations and calculate the relative risk. Results: thrombophilia was present in 72.0% of pregnant women with SLE and in 6.0% of patients in the control group. A significant association was found between the presence of SLE and serum markers for hereditary thrombophilia / antiphospholipid antibodies (p<0.05). The relative risks for antiphospholipid antibodies were 13.20 (ICR95%= 1.81 - 96.46) in pregnant women with SLE, 7.26 (CI95%= 1.77 - 29.86) for the presence of serum markers of hereditary thrombophilia and 7.92 (CI95%= 2.62 - 3.94) for the presence of hereditary thrombophilia and/or antiphospholipid antibodies. Conclusions: the identification of markers for hereditary and/or acquired thrombophilia in pregnant women with lupus may be clinically useful to determine which patients have a higher risk of obstetric complications.

Cold Lymphocytotoxins in Connective Tissue Disorders

1979 ◽  
Vol 24 (1) ◽  
pp. 5-8 ◽  
Author(s):  
J. D. Browning ◽  
Heather M. Dick ◽  
R. Sturrock ◽  
D. Grennan ◽  
W. C. Dick
Keyword(s):  
Connective Tissue ◽  
Lupus Erythematosus ◽  
Control Group ◽  
Blood Transfusions ◽  
Connective Tissue Disorders ◽  
Systemic Lupus ◽  
Control Groups ◽  
Lymphocytotoxic Antibodies ◽  
Close Proximity ◽  
Absorption Studies

Sixty-eight patients with various connective tissue disorders, 5 relatives of patients and 26 members of staff from the Centre for Rheumatic Diseases were studied for the presence in their sera of cold lymphocytotoxic antibodies. Antibodies were found in 71 per cent of patients with systemic lupus erythematosus, 27 per cent of patients with rheumatoid arthritis, 0 per cent of the small group of relatives and 3.8 per cent of the controls. Absorption studies did not show T or B specificity of the antibodies. The control group, working in close proximity to the patients or their sera did not show any increased incidence of antibodies as compared to control groups of other studies. Red blood cell anti I or HI was found in the sera of 28 per cent of those with cold lymphocytotoxic antibodies. No correlation was found between the presence of the antibodies and number of blood transfusions or pregnancies, increasing age, R 3 titre or antinuclear factor.

Uncommon Connective Tissue Disorders in Childhood

1974 ◽  
Vol 19 (2) ◽  
pp. 65-75 ◽  
Author(s):  
K. M. Goel ◽  
R. A. Shanks
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Failure ◽  
Connective Tissue ◽  
Lupus Erythematosus ◽  
Placental Transfer ◽  
Progressive Systemic Sclerosis ◽  
The Other ◽  
Connective Tissue Disorders ◽  
Systemic Lupus ◽  
Lupus Syndrome

Nineteen cases of the rarer connective tissue disorders diagnosed between 1948 and 1972 have been reviewed. Of these 6 were of systemic lupus erythematosus (SLE), 3 of dermatomyositis and 5 each of progressive systemic sclerosis (PSS) and polyarteritis nodosa (PAN). Of the 6 cases of SLE, 4 were of true SLE, one of ethosuximide induced lupus syndrome and one newborn with placental transfer of lupus erythematosus factor. Three cases of true SLE died of renal failure. None of the patients with dermatomyositis or PSS died. Of the 5 cases of PAN, 2 died and one could not be traced. The disease is quiescent in the other two.

Sign in / Sign up

Export Citation Format

Share Document